Unmet needs of biochemical biomarkers for human prion diseases

References

• Zerr I. Laboratory diagnosis of Creutzfeldt-Jakob disease. N Engl J Med. 2022;386(14):1345–1350. doi: 10.1056/NEJMra2119323
   PubMed Web of Science ®Google Scholar
• Levy SR, Chiappa KH, Burke CJ, et al. Early evolution and incidence of electroencephalographic abnormalities in Creutzfeldt-Jakob disease. J Clin Neurophysiol. 1986;3(1):1–21. doi: 10.1097/00004691-198601000-00001
   PubMed Web of Science ®Google Scholar
• Zerr I, Bodemer M, Otto M, et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet. 1996;348(9031):846–849. doi: 10.1016/S0140-6736(96)08077-4
   PubMed Web of Science ®Google Scholar
• Harrington MG, Merril CR, Asher DM, et al. Abnormal proteins in the cerebrospinal fluid of patients with creutzfeldt–Jakob Disease. N Engl J Med. 1986;315(5):279–283. doi: 10.1056/NEJM198607313150502
   PubMed Web of Science ®Google Scholar
• Hsich G, Kenney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996;335(13):924–930. doi: 10.1056/NEJM199609263351303
   PubMed Web of Science ®Google Scholar
• Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(14):1499–1506. doi: 10.1212/WNL.0b013e31826d5fc3
   PubMed Web of Science ®Google Scholar
• Schmitz M, Cramm M, Llorens F, et al. The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc. 2016;11(11):2233–2242. doi: 10.1038/nprot.2016.120
   PubMed Web of Science ®Google Scholar
• Hermann P, Appleby B, Brandel J-P, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021;20(3):235–246. doi: 10.1016/S1474-4422(20)30477-4
   PubMed Web of Science ®Google Scholar
• Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(10):2659–2668. doi: 10.1093/brain/awp191
   PubMedGoogle Scholar
• Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76(20):1711–1719. doi: 10.1212/WNL.0b013e31821a4439
   PubMed Web of Science ®Google Scholar
• Lee H, Rosenmann H, Chapman J, et al. Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain. 2009;132(10):2680–2687. doi: 10.1093/brain/awp064
   PubMedGoogle Scholar
• Yasuda M, Sugiyama A, Hokkoku H, et al. Propagation of diffusion-weighted MRI abnormalities in the preclinical stage of sporadic Creutzfeldt-Jakob disease. Neurology. 2022;99(16):699–702. doi: 10.1212/WNL.0000000000201221
   PubMed Web of Science ®Google Scholar
• Koizumi R, Ueda N, Mugita A, et al. Case report: Extremely early detection of preclinical magnetic resonance imaging abnormality in creutzfeldt–Jakob disease with the V180I mutation. Front Neurol. 2021;12:751750. doi: 10.3389/fneur.2021.751750
   PubMed Web of Science ®Google Scholar
• Zanusso G, Camporese G, Ferrari S, et al. Long-term preclinical magnetic resonance imaging alterations in sporadic creutzfeldt–Jakob disease. Ann Neurol. 2016;80(4):629–632. doi: 10.1002/ana.24757
   PubMed Web of Science ®Google Scholar
• Alvarez FJ, Bisbe J, Bisbe V, et al. Magnetic resonance imaging findings in pre-clinical Creutzfeldt-Jakob disease. Int J Neurosci. 2005;115(8):1219–1225. doi: 10.1080/00207450590914491
   PubMed Web of Science ®Google Scholar
• Wilham JM, Orrú CD, Bessen RA, et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog. 2010;6(12):e1001217. doi: 10.1371/journal.ppat.1001217
   PubMed Web of Science ®Google Scholar
• Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17(2):175–178. doi: 10.1038/nm.2294
   PubMed Web of Science ®Google Scholar
• McGuire LI, Peden AH, Orrú CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic creutzfeldt–Jakob disease. Ann Neurol. 2012;72(2):278–285. doi: 10.1002/ana.23589
   PubMed Web of Science ®Google Scholar
• Hermann P, Laux M, Glatzel M, et al. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology. 2018;91(4):e331–e338. doi: 10.1212/WNL.0000000000005860
   PubMed Web of Science ®Google Scholar
• Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. Neurology. 2020;95(8):e1017–e1026. doi: 10.1212/WNL.0000000000010086
   PubMed Web of Science ®Google Scholar
• Zerr I, Villar-Piqué A, Hermann P, et al. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther. 2021;13(1):86. doi: 10.1186/s13195-021-00815-6
   PubMed Web of Science ®Google Scholar
• Thompson AGB, Anastasiadis P, Druyeh R, et al. Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol Psychiatry. 2021;26(10):5955–5966. doi: 10.1038/s41380-021-01045-w
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Baiardi S, Ladogana A, et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J Neurol Neurosurg Psychiatry. 2020;91(11):1181–1188. doi: 10.1136/jnnp-2020-323826
   PubMed Web of Science ®Google Scholar
• Hermann P, Canaslan S, Villar-Piqué A, et al. Plasma neurofilament light chain as a biomarker for fatal familial insomnia. Eur J Neurol. 2022 Jun;29(6):1841–1846. doi: 10.1111/ene.15302
   PubMed Web of Science ®Google Scholar
• Zanusso G, Ferrari S, Cardone F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease.
   Google Scholar
• Venkatraghavan V, Pascuzzo R, Bron EE, et al. A discriminative event-based model for subtype diagnosis of sporadic Creutzfeldt-Jakob disease using brain MRI. Alzheimers Dement. 2023;19(8):3261–3271. doi: 10.1002/alz.12939
   PubMed Web of Science ®Google Scholar
• Yasuda M, Sugiyama A, Hokkoku H, et al. S. Propagation of diffusion-weighted MRI abnormalities in the preclinical stage of sporadic Creutzfeldt-Jakob disease. Neurology. 2022;99(16):699–702. doi: 10.1212/WNL.0000000000201221
   PubMed Web of Science ®Google Scholar
• Mok TH, Nihat A, Majbour N, et al. Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. Brain. 2023;146(6):2570–2583. doi: 10.1093/brain/awad101
   PubMed Web of Science ®Google Scholar
• Krasnianski A, Heinemann U, Ponto C, et al. Clinical findings and diagnosis in genetic prion diseases in Germany. Eur J Epidemiol. 2016 Feb;31(2):187–196. doi: 10.1007/s10654-015-0049-y
   PubMed Web of Science ®Google Scholar
• Rus T, Mlakar J, L L, et al. Sporadic creutzfeldt–Jakob disease is associated with reorganization of metabolic connectivity in a pathological brain network. Euro J Neurol. 2023 Apr;30(4):1035–1047. doi: 10.1111/ene.15669
   PubMed Web of Science ®Google Scholar
• Orru CD, Yuan J, Appleby BS, et al. Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci Transl Med. 2017;9(417). doi: 10.1126/scitranslmed.aam7785
   PubMed Web of Science ®Google Scholar
• Orru CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt–Jakob disease using Nasal Brushings. N Engl J Med. 2014;371(6):519–529. doi: 10.1056/NEJMoa1315200
   PubMed Web of Science ®Google Scholar
• Schmitz M, Silva Correia S, Hermann P, et al. Detection of prion protein seeding activity in tear fluids. N Engl J Med. 2023;388(19):1816–1817. doi: 10.1056/NEJMc2214647
   PubMed Web of Science ®Google Scholar
• Schmitz M, Villar-Piqué A, Hermann P, et al. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain. 2022;145(2):700–712. doi: 10.1093/brain/awab350
   PubMed Web of Science ®Google Scholar
• Vallabh SM, Minikel EV, Williams VJ, et al. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Med. 2020;18(1):140. doi: 10.1186/s12916-020-01608-8
   PubMed Web of Science ®Google Scholar
• Bregman N, Shiner T, Kavé G, et al. The natural history study of preclinical genetic Creutzfeldt-Jakob disease (CJD): a prospective longitudinal study protocol. BMC neurol. 2023;23(1):151. doi: 10.1186/s12883-023-03193-8
   PubMed Web of Science ®Google Scholar
• Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20(3):203–212. doi: 10.1016/S1474-4422(20)30449-X
   PubMed Web of Science ®Google Scholar
• Palmqvist S, Rossi M, Hall S, et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat Med. 2023;29(8):1971–1978. doi: 10.1038/s41591-023-02450-0
   PubMed Web of Science ®Google Scholar
• Llorens F, Rübsamen N, Hermann P, et al. A prognostic model for overall survival in sporadic Creutzfeldt-Jakob disease. Alzheimers Dement. 2020;16(10):1438–1447. doi: 10.1002/alz.12133
   PubMed Web of Science ®Google Scholar